Septerna to Participate in Upcoming Investor and Industry Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Septerna, a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced that members of the management team, including Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder, and Liz Bhatt, MS, MBA, Chief Operating Officer, will participate in the following investor and industry conferences:

Evercore ISI 2024 Emerging Private Biotech Conference
Presentation: Wednesday, February 28, 2024, at 2:50 p.m. ET.
Location: Virtual.

TD Cowen 44th Annual Health Care Conference
Participation: Monday, March 4, 2024.
Location: Boston, MA.

Fierce Biotech 2024 Business Development and Licensing Summit
Panel: “Dynamics and Structures for Negotiating and Evaluating Platform Deals” on Monday, March 11, 2024, at 1:15 p.m. PT.
Location: San Francisco, CA.

Leerink Partners 2024 Global Biopharma Conference
Participation: Wednesday, March 13, 2024.
Location: Miami, FL.

About Septerna

Septerna, Inc. is a biotechnology company focused on advancing novel, oral small molecule medicines targeting the entire class of G protein-coupled receptors (GPCRs). The company’s Native Complex Platform™ recapitulates GPCRs with their native structure, function, and dynamics outside of the cellular environment to rapidly apply new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. Septerna was launched in 2022 by scientific founders who have made groundbreaking GPCR discoveries. For more information, please visit www.septerna.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240222273396/en/

Media
Cory Tromblee
Scient PR
[email protected]

Investor
Renee Leck
THRUST Strategic Communications
[email protected]

Source: Septerna

You May Also Be Interested In

• TiVo OS Unveils Major Platform Enhancements at IFA 2026, Expanding AI-Powered Discovery, Free Streaming, Live Sports and Interactive TV Experiences
• 10 Top 1000x Crypto Picks in this Altcoin Season: Apeing Eyes Massive Upside Potential With $0.0001 Entry Price
• Faraday Future Advances Its “Built in USA” Strategy, Participates in the FCC’s Public-Comment Process, and Signs a U.S. Compliance and Localization Advisory Agreement with AIBOT